Latest Insider Transactions at Prelude Therapeutics Inc (PRLD)
This section provides a real-time view of insider transactions for Prelude Therapeutics Inc (PRLD). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Prelude Therapeutics Inc to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Prelude Therapeutics Inc's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 04
2024
|
Jane Huang President, CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,349
-5.02%
|
$6,698
$2.0 P/Share
|
|
Oct 04
2024
|
Jane Huang President, CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
9,375
+12.33%
|
-
|
|
Jul 04
2024
|
Jane Huang President, CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,347
-5.52%
|
$10,041
$3.6 P/Share
|
|
Jul 04
2024
|
Jane Huang President, CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
9,375
+13.39%
|
-
|
|
Apr 04
2024
|
Jane Huang President, CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,347
-6.13%
|
$13,388
$4.74 P/Share
|
|
Apr 04
2024
|
Jane Huang President, CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
9,375
+14.65%
|
-
|
|
Jan 04
2024
|
Jane Huang President, CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,844
-7.83%
|
$11,532
$3.77 P/Share
|
|
Jan 04
2024
|
Jane Huang President, CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
9,375
+16.03%
|
-
|
|
Oct 04
2023
|
Jane Huang President, CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
9,375
+19.09%
|
-
|
|
Jul 04
2023
|
Jane Huang President, CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,242
-9.65%
|
$12,968
$4.65 P/Share
|
|
Jul 04
2023
|
Jane Huang President, CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
9,375
+21.82%
|
-
|
|
May 25
2023
|
Krishna Vaddi CEO |
BUY
Open market or private purchase
|
Direct |
900
+0.08%
|
$4,500
$5.31 P/Share
|
|
May 24
2023
|
Krishna Vaddi CEO |
BUY
Open market or private purchase
|
Direct |
1,000
+0.09%
|
$5,000
$5.01 P/Share
|
|
May 24
2023
|
Bryant David Lim CLO, Interim CFO, Corp Sec. |
BUY
Open market or private purchase
|
Direct |
2,400
+50.0%
|
$12,000
$5.39 P/Share
|
|
May 23
2023
|
Laurent Chardonnet Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+10.6%
|
$25,000
$5.5 P/Share
|
|
May 23
2023
|
Krishna Vaddi CEO |
BUY
Open market or private purchase
|
Direct |
11,856
+1.1%
|
$59,280
$5.63 P/Share
|
|
May 22
2023
|
Orbimed Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
869,565
+7.91%
|
$4,347,825
$5.75 P/Share
|
|
May 22
2023
|
David P Bonita |
BUY
Open market or private purchase
|
Indirect |
869,565
+7.91%
|
$4,347,825
$5.75 P/Share
|
|
Apr 06
2023
|
Jane Huang President, CMO |
SELL
Open market or private sale
|
Direct |
13,280
-35.41%
|
$79,680
$6.12 P/Share
|
|
Apr 04
2023
|
Jane Huang President, CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
37,500
+50.0%
|
-
|
|
Dec 20
2022
|
Krishna Vaddi CEO |
BUY
Open market or private purchase
|
Indirect |
19,188
+13.72%
|
$95,940
$5.13 P/Share
|
|
Dec 08
2022
|
Laurent Chardonnet Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+21.8%
|
$40,000
$4.76 P/Share
|
|
Jun 01
2022
|
Laurent Chardonnet Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+28.99%
|
$40,000
$4.23 P/Share
|
|
Mar 31
2022
|
Andrew Combs Chief Chemistry Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
36,062
+10.59%
|
$36,062
$1.89 P/Share
|
|
Mar 21
2022
|
Laurent Chardonnet Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,500
+30.95%
|
$45,500
$7.51 P/Share
|
|
Dec 15
2021
|
Deborah Morosini EVP, Chief of Clinical Affairs |
SELL
Open market or private sale
|
Direct |
28,751
-98.48%
|
$373,763
$13.0 P/Share
|
|
Dec 15
2021
|
Deborah Morosini EVP, Chief of Clinical Affairs |
BUY
Exercise of conversion of derivative security
|
Direct |
28,751
+46.71%
|
$201,257
$7.37 P/Share
|
|
Dec 14
2021
|
Andrew Combs Chief Chemistry Officer |
BUY
Open market or private purchase
|
Direct |
4,000
+1.47%
|
$44,000
$11.6 P/Share
|
|
Dec 13
2021
|
Andrew Combs Chief Chemistry Officer |
BUY
Open market or private purchase
|
Direct |
4,000
+1.49%
|
$48,000
$12.12 P/Share
|
|
Dec 13
2021
|
Krishna Vaddi CEO |
BUY
Grant, award, or other acquisition
|
Direct |
8,000
+0.75%
|
$96,000
$12.13 P/Share
|
|
Dec 13
2021
|
Laurent Chardonnet Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+38.46%
|
$60,000
$12.28 P/Share
|
|
Nov 16
2021
|
Deborah Morosini EVP, Chief of Clinical Affairs |
SELL
Open market or private sale
|
Direct |
28,751
-72.25%
|
$460,016
$16.15 P/Share
|
|
Nov 16
2021
|
Deborah Morosini EVP, Chief of Clinical Affairs |
BUY
Exercise of conversion of derivative security
|
Direct |
28,751
+49.62%
|
$345,012
$12.85 P/Share
|
|
Oct 05
2021
|
David J Mauro Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
15,000
-75.07%
|
$465,000
$31.21 P/Share
|
|
Oct 05
2021
|
David J Mauro Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
$15,000
$1.89 P/Share
|
|
Sep 07
2021
|
David J Mauro Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
15,000
-62.72%
|
$540,000
$36.87 P/Share
|
|
Sep 07
2021
|
David J Mauro Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
$15,000
$1.89 P/Share
|
|
Sep 02
2021
|
Christopher Pierce EVP and Chief of Business Oper |
SELL
Open market or private sale
|
Direct |
17,000
-39.88%
|
$697,000
$41.44 P/Share
|
|
Sep 02
2021
|
Christopher Pierce EVP and Chief of Business Oper |
BUY
Exercise of conversion of derivative security
|
Direct |
17,000
+45.03%
|
$204,000
$12.85 P/Share
|
|
Aug 27
2021
|
Peggy Scherle Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
6,014
-1.13%
|
$216,504
$36.21 P/Share
|
|
Aug 27
2021
|
Peggy Scherle Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,014
+3.25%
|
$6,014
$1.43 P/Share
|
|
Aug 26
2021
|
Peggy Scherle Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,700
-0.97%
|
$59,500
$35.19 P/Share
|
|
Aug 26
2021
|
Peggy Scherle Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,700
+0.96%
|
$1,700
$1.43 P/Share
|
|
Aug 25
2021
|
Brian Piper Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
8,333
-62.53%
|
$274,989
$33.33 P/Share
|
|
Aug 25
2021
|
Brian Piper Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,333
+50.0%
|
$8,333
$1.89 P/Share
|
|
Aug 13
2021
|
Peggy Scherle Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,286
-1.3%
|
$80,010
$35.07 P/Share
|
|
Aug 13
2021
|
Peggy Scherle Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,286
+0.65%
|
$2,286
$1.66 P/Share
|
|
Aug 05
2021
|
David J Mauro Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
15,000
-65.63%
|
$465,000
$31.44 P/Share
|
|
Aug 05
2021
|
David J Mauro Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
$15,000
$1.89 P/Share
|
|
Jul 27
2021
|
Peggy Scherle Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
20,000
-5.2%
|
$700,000
$35.77 P/Share
|